Schizophrenia is a chronic, severe, and highly heterogeneous psychiatric disorder. Current antipsychotic medications show limited effectiveness in treating negative symptoms and cognitive deficits. Accumulating evidence suggests that dysfunction of inhibitory γ-aminobutyric acid (GABA) neurons, leading to inhibitory circuit dysregulation, plays a pivotal role in the pathophysiology of the disorder. Recent advances in induced pluripotent stem cells (iPSCs) and brain organoid technologies have provided more accurate human-based models of schizophrenia, offering new avenues to investigate the complex neurodevelopmental mechanism of schizophrenia and to explore cell replacement therapies. Preclinical studies have demonstrated that transplantation of specific types of GABAergic interneuron precursors into the brain can selectively improve negative symptoms and cognitive deficits in animal models, highlighting considerable translational potential. However, the transition from bench to bedside still faces multiple technical and ethical challenges, enhancing cell differentiation efficiency, ensuring long-term safety of transplanted cells, achieving precise control and functional integration of neuronal subtypes, understanding circuit-specific contributions to different symptom domains, and establishing rigorous ethical and regulatory frameworks. In summary, inhibitory GABAergic interneuron-based cell therapy provides a novel theoretical and perspective foundation for improving negative and cognitive symptoms of schizophrenia. Despite significant challenges ahead, its prospects remain highly promising.

Schizophrenia is a chronic, severe, and highly heterogeneous psychiatric disorder. Current antipsychotic medications show limited effectiveness in treating negative symptoms and cognitive deficits. Accumulating evidence suggests that dysfunction of inhibitory γ-aminobutyric acid (GABA) neurons, leading to inhibitory circuit dysregulation, plays a pivotal role in the pathophysiology of the disorder. Recent advances in induced pluripotent stem cells (iPSCs) and brain organoid technologies have provided more accurate human-based models of schizophrenia, offering new avenues to investigate the complex neurodevelopmental mechanism of schizophrenia and to explore cell replacement therapies. Preclinical studies have demonstrated that transplantation of specific types of GABAergic interneuron precursors into the brain can selectively improve negative symptoms and cognitive deficits in animal models, highlighting considerable translational potential. However, the transition from bench to bedside still faces multiple technical and ethical challenges, enhancing cell differentiation efficiency, ensuring long-term safety of transplanted cells, achieving precise control and functional integration of neuronal subtypes, understanding circuit-specific contributions to different symptom domains, and establishing rigorous ethical and regulatory frameworks. In summary, inhibitory GABAergic interneuron-based cell therapy provides a novel theoretical and perspective foundation for improving negative and cognitive symptoms of schizophrenia. Despite significant challenges ahead, its prospects remain highly promising.

Incretin-based therapies are now being widely used in type 2 diabetes as a new type of antidiabetic drugs,with their efficacy and safety having been confirmed.However,there are relatively few researches carried out in type 1 diabetes.A variety of clinical studies (mainly in type 2 diabetes) have shown that incretin-based therapy could effectively improve glucose control.In this article,the clinieal application of incretin-based therapy in type 1 diabetes will be reviewed and commented from the prospective of clinical studies,combined with animal experiments.